Neuroscience Today—June 17, 2026

This week’s Neuroscience update highlights regulatory decisions, late-stage clinical data, pipeline expansion through acquisition activity, and mixed development outcomes across neuromuscular, sleep, migraine, and neuroimaging programs.

In Today’s Newsletter

Dive deeper

🧬 Novartis del-brax hits FSHD biomarker endpoints [1] [US, EU • 11 Jun 2026]

https://www.novartis.com/news/media-releases/novartis-delpacibart-braxlosiran-del-brax-phase-iii-study-facioscapulohumeral-muscular-dystrophy-fshd-meets-primary-biomarker-endpoint
Context: FORTITUDE Phase I/II biomarker cohort evaluated delpacibart braxlosiran (del-brax), an investigational antibody oligonucleotide conjugate for FSHD.
Key point: Novartis said FORTITUDE met primary and key secondary endpoints, reducing KHDC1L (cDUX) and creatine kinase biomarkers.
Implication: May influence prescriber choice and payer reviews pending full data.

🧠 Otsuka completes Transcend Therapeutics acquisition [2] [US • 15 Jun 2026]

https://www.otsuka.co.jp/en/company/newsreleases/2026/20260615_1.html
Context: Otsuka acquired Transcend Therapeutics for USD 700 million upfront, with up to USD 525 million in contingent consideration.
Key point: The deal adds TSND-201 (methylone), a rapid-acting neuroplastogen in Phase 3 EMPOWER-1 for PTSD.
Implication: Signals pipeline investment and modality expansion.

⚠️ Sanofi stops MOBILIZE riliprubart Phase 3 in refractory CIDP [3] [EU • 10 Jun 2026]

https://www.sanofi.com/en/media-room/press-releases/2026/2026-06-10-05-00-00-3309444
Context: MOBILIZE (NCT06290128) studied riliprubart in chronic inflammatory demyelinating polyneuropathy refractory to standard-of-care treatment.
Key point: Sanofi will stop MOBILIZE after an independent interim analysis found the study unlikely to provide sufficient efficacy.
Implication: May influence prescriber choice and payer reviews pending full data.

🖥️ Bayer wins US approval for Ambelvist MRI contrast agent [4] [US • 15 Jun 2026]

https://www.bayer.com/media/en-us/bayers-low-dose-mri-contrast-agent-approved-in-us/
Context: FDA approved Ambelvist (gadoquatrane), an intravenous macrocyclic gadolinium-based MRI contrast agent.
Key point: The approval covers contrast-enhanced MRI to detect and visualize lesions with abnormal vascularity in CNS and non-CNS body regions.
Implication: Introduces competition that may affect pricing and formulary access.

💊 AbbVie Aquipta recommended by NICE for acute migraine [5] [UK • 10 Jun 2026]

https://pharmatimes.com/news/aquipta-recommended-by-nice-for-acute-migraine-treatment/
Context: NICE recommended Aquipta (atogepant) for eligible adults with acute migraine with or without aura in England and Wales.
Key point: Eligibility requires prior inadequate response or inability to take at least two triptans, plus insufficient response to NSAIDs and paracetamol.
Implication: May expand screening, initiation, and follow-up at scale.

🌙 Takeda oveporexton Phase 3 data show NT1 symptom gains [6] [Japan, US • 15 Jun 2026]

https://www.takeda.com/newsroom/newsreleases/2026/oveporexton-phase-3-narcolepsy-type-1/
Context: FirstLight and RadiantLight are global, multicenter, placebo-controlled Phase 3 studies of oveporexton (TAK-861) in narcolepsy type 1.
Key point: Takeda reported improvements in daily function, cognition, and nighttime sleep versus placebo across secondary and exploratory endpoints.
Implication: May influence prescriber choice and payer reviews pending full data.

📊 cTAP DMD prognostic score predicts loss of ambulation [7] [US • 15 Jun 2026]

https://www.businesswire.com/news/home/20260615221008/en/cTAP-Announces-Novel-Prognostic-Score-Developed-for-Duchenne-Muscular-Dystrophy-Patients-Offers-Improved-Prediction-of-Loss-of-Ambulation
Context: cTAP published an open-access prognostic score for Duchenne muscular dystrophy using rise from floor and 10-meter walk/run measures.
Key point: The score stratified patients into five risk groups for loss of ambulation and was validated in an independent dataset.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

Why it matters

Neuromuscular disease remains active, with Novartis advancing del-brax in FSHD and cTAP adding DMD prognostic tools. [1][7]
Psychiatry pipeline activity is intensifying, with Otsuka adding TSND-201 for PTSD through Transcend. [2]
CIDP development risk remains visible after Sanofi’s MOBILIZE stop for riliprubart. [3]
Access and regulatory decisions shaped this week’s news, including Bayer’s US approval and AbbVie’s NICE recommendation. [4][5]
Takeda’s oveporexton data support a broader symptom-targeting approach in narcolepsy type 1. [6]

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Neuroscience archive on our research hub page.

FAQ

What is Novartis del-brax for FSHD?

Delpacibart braxlosiran (del-brax) is an investigational antibody oligonucleotide conjugate for facioscapulohumeral muscular dystrophy. Novartis said FORTITUDE met biomarker endpoints and Phase III is enrolling. [1]

What did Otsuka gain from Transcend Therapeutics?

Otsuka gained Transcend Therapeutics and TSND-201 (methylone), a rapid-acting neuroplastogen being studied for PTSD. EMPOWER-1 Phase 3 is underway in the US. [2]

Why is Sanofi stopping MOBILIZE?

Sanofi said an independent data monitoring committee found MOBILIZE, a Phase 3 study of riliprubart in refractory CIDP, unlikely to provide sufficient efficacy. No riliprubart-related safety signals were identified in the interim analysis. [3]

What is Bayer’s Ambelvist?

Ambelvist is Bayer’s brand name for gadoquatrane, an FDA-approved macrocyclic gadolinium MRI contrast agent. It is indicated for contrast-enhanced MRI in adult and pediatric patients, including term neonates. [4]

Who may access AbbVie Aquipta after the NICE recommendation?

NICE recommended Aquipta (atogepant) for eligible adults in England and Wales with acute migraine, after specified prior treatment failures or intolerance. The recommendation follows MHRA marketing authorisation in April 2026. [5]

What did Takeda report for oveporexton?

Takeda reported Phase 3 secondary and exploratory endpoint data showing improvements in daily functioning, cognition, and nighttime sleep in narcolepsy type 1. Regulatory submissions are under review. [6]

Entities / Keywords

Novartis: delpacibart braxlosiran, del-brax, FORTITUDE, FSHD, KHDC1L, cDUX, creatine kinase, Avidity Biosciences
Otsuka: Otsuka Pharmaceutical, Otsuka America, Transcend Therapeutics, TSND-201, methylone, PTSD, IMPACT-1, EMPOWER-1
Sanofi: riliprubart, MOBILIZE, VITALIZE, CIDP, chronic inflammatory demyelinating polyneuropathy
Bayer: gadoquatrane, Ambelvist, macrocyclic gadolinium-based contrast agent, mGBCA, QUANTI, MRI
AbbVie: Aquipta, atogepant, NICE, MHRA, migraine, acute migraine, Eclipse
Takeda: oveporexton, TAK-861, orexin receptor 2 agonist, OX2R, narcolepsy type 1, NT1, FirstLight, RadiantLight, SLEEP 2026
cTAP: Collaborative Trajectory Analysis Project, Duchenne muscular dystrophy, DMD, loss of ambulation, rise from floor, 10-meter walk/run